GOLDENWELL BIOTECH, INC. (GWLL)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2024, GOLDENWELL BIOTECH, INC. reported revenue of $139, down 92.4% from the prior year. The company ran a net loss, with a net margin of -94602.9% and a gross margin of 46.0%. It held $224.2K in total assets against $271.4K in total liabilities.
Key ratios (FY2024)
46.0%
Gross margin
-88559.7%
Operating margin
-94602.9%
Net margin
-92.4%
Revenue growth (YoY)
| Metric (FY) | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $139 | $1.8K | $47.8K | $16.0K | $0 | $0 | — |
| Cost of Revenue | $75 | $1.2K | $22.6K | $7.6K | $0 | $0 | — |
| Gross Profit | $64 | $666 | $25.2K | $8.4K | $0 | $0 | — |
| Operating Income | -$123.1K | -$115.8K | -$985.1K | -$118.3K | — | — | — |
| Net Income | -$131.5K | -$117.4K | -$985.1K | -$117.0K | -$6.3K | -$2.3K | — |
| EPS (Diluted) | $0.00 | $0.00 | — | — | — | — | — |
| Total Assets | $224.2K | $228.1K | $248.4K | $461.0K | $248.6K | $246.6K | — |
| Total Liabilities | $271.4K | $143.8K | $46.8K | $159.3K | $0 | $0 | — |
| Shareholders' Equity | -$47.2K | $84.3K | $201.6K | $301.7K | $248.6K | $246.6K | — |
| Cash & Equivalents | — | — | $46.0K | $213.6K | $248.6K | $246.6K | $0 |
| Operating Cash Flow | -$123.1K | -$113.2K | -$1.07M | -$205.1K | -$6.3K | -$2.3K | — |
| Shares Outstanding | 99.00M | 99.00M | 99.00M | 91.50M | 91.50M | 80.00M | — |